Yves Quintin

Partner

  • Yves Quintin
  • Phone: +1 215 979 1289

    Yves Quintin - LinkedIn Import to Address Book

  • Duane Morris LLP
    30 South 17th Street
    Philadelphia, PA 19103-4196
    USA

Yves Quintin practices in the areas of corporate law, mergers and acquisitions, venture capital, finance and international transactions.

Admitted to practice in New York and Paris, he formerly served as a legal and economic advisor in the Cabinet of the Governor of French Guiana. Mr. Quintin is the former chair of the International Law Committee of the Philadelphia Bar Association and the International Law Committee of the Young Lawyers Division of the American Bar Association. Fluent in French and conversant in German, he has authored numerous articles, published in English and French, on various aspects of international transactions, most recently on the violation of U.S. embargoes by BNP Paribas (2014) and on credit default swaps and the Greek debt restructuring (2012), and has also lectured in the United States and abroad on mergers and acquisitions and related matters. His book on M&A, Les Fusions-Acquisitions aux USA, was published by Les Editions Bruylant (Brussels) and Yvon Blais (Québec) in 2005. Mr. Quintin has taught a mergers and acquisitions class at the University of Pennsylvania Law School.

Mr. Quintin is a graduate of the University of Michigan Law School (LL.M.), the University of Paris-IX-Dauphine (D.E.A. (all but dissertation) in economics), the University of Paris-V (LL.B.), l'École Supérieure de Commerce de Paris (M.B.A.) and Lycée Louis Le Grand (Paris). He is an avid competitive squash player, a soccer fan and windsurfing enthusiast. His personal website is www.fusacqusa.com.

Representative Matters

    Mergers and Acquisitions

  • Represented Onspira in its acquisition by Altavant Sciences GmbH for $10 million, plus milestones and royalties.
  • Represented investors in connection with the acquisition of a majority interest in a licensed grower and distributor of cannabis in Louisiana.
  • Represented the shareholders of Teletronics Technology Corporation in the sale of the company to Curtis-Wright Controls for $233 million.
  • Represented Vicept Therapeutics in its acquisition by Allergan for a $75 million cash up-front payment plus up to an additional $200 million in milestone payments, as well as (undisclosed) sales earnouts.
  • Represented biopharmaceutical company Ception Therapeutics in its acquisition by Cephalon for $250 million and up to $500 million in milestone payments.
  • Represented Ception Therapeutics in a $100 million option agreement with Cephalon, pursuant to which Cephalon acquired an option to purchase all of the stock of Ception.
  • Represented shareholders in the $200 million sale of stock of the holding company of a major media company (Fortune 100) and related reorganization.
  • Represented Ception Therapeutics in its merger with Fulcrum Pharmaceuticals.
  • Represented a mortgage insurance company in the divestiture of a structured-settlements subsidiary ($26.5 million).

    • Cross-Border Mergers and Acquisitions

  • Represented a French listed company in its acquisition of a Hong Kong and US-based textile manufacturer and distributor for $66 million.
  • Represented a Québec company in connection with its acquisition of the assets of a U.S. stone mining company.
  • Represented a pharmaceutical company in connection with the disposition of the rights to certain EU-approved drugs to a French pharmaceutical company.
  • Represented a major French transportation company in the $12 million divestiture of a majority interest in a charter bus company.
  • Represented a major French transportation company in connection with the acquisition of minority interests in a transportation company held by shareholders/managers for an undisclosed amount.
  • Represented a French listed company in connection with the acquisition of a U.S. manufacturer of surface protection films for $22 million.
  • Represented a US pharmaceutical company in connection with the disposition of certain drug assets to a South African company for $14 million.
  • Represented the shareholders of a Québec-based company operating in the diet industry in connection with the acquisition of a majority interest by a major U.S. private equity firm in a transaction valued at CAD $563 million.
  • Represented a major French transportation company in connection with the acquisition of a U.S. sightseeing business for an undisclosed amount.
  • Represented a major French sports management company in connection with the acquisition of a golf events management company for an undisclosed amount.
  • Represented Ceptaris Therapeutics in its acquisition by Actelion (Switzerland) for $250 million cash plus undisclosed milestone payments and sales earnouts.
  • Represented a French CAC 40 company in connection with the sale of its wind-to-energy subsidiary for $81 million.
  • Represented Iroko Holdings S.A. (Luxembourg) in its acquisition of iCeutica Inc. (Australia), a nanotechnology platform company, for an undisclosed amount.
  • Represented a UK company, Science Navigation Group, in connection with the divestiture of its Israeli navigation software subsidiary, Telmap, to Intel (for a reported $300 million).
  • Represented a major Canadian (TSX) company in connection with numerous acquisitions of companies in the US.
  • Represented a major US public pension fund in connection with a $100 million preferred stock investment in an Irish company.
  • Represented a major US public pension fund in connection with a $40 million convertible notes investment in an Irish company.
  • Represented a listed French company in connection with several acquisitions in the US in the telecommunications field.
  • Represented a listed French company in connection with $110 million acquisition in the surface protection industry.
  • Represented a US subsidiary of major French minerals company in connection with several investments in China.
  • Represented a major US engineering design software company in connection with its acquisition of Canadian software company.
  • Represented a US manufacturer in connection with the purchase of an interest in a Hungarian company.
  • Represented a US pharmaceutical company in connection with a $26 million joint venture with a South African company relating to the worldwide distribution of a drug.
  • Represented US shareholders in connection with the divestiture of their interests in a privately owned German software company.
  • Represented a major French company (CAC 40) in connection with several acquisitions in the US.
  • Advised a major French company (CAC 40) in connection with a large potential claim ($1.5 billion) from a counterparty in an M&A dispute.
  • Represented a UK company in connection with the sale of a gold mine in Tanzania to a Chinese acquirer.

    • Venture Capital and Private Equity

  • Represented a start-up diagnostics company in connection with the acquisition of intellectual property from a university and $3 million “seed” raise.
  • Represented Velicept Therapeutics, a specialty pharmaceutical company, in its acquisition of AltheRx, Inc. and $20 million Series B financing.
  • Represented a start-up oncology company in connection with a $1 million convertible notes “seed” raise.
  • Represented a start-up artificial intelligence company in connection with a $500,000 convertible notes “seed” raise.
  • Represented a start-up pharmaceutical company in connection with a $1 million secured convertible promissory notes issue.
  • Represented an artificial intelligence company in connection with a $4.6 million series B financing.
  • Represented Ralexar Therapeutics in connection with a $6.9 million Series B financing.
  • Represented Velicept Therapeutics in connection with a convertible notes financing.
  • Represented Aclaris Therapeutics, Inc., a specialty pharmaceutical company with a focus on the development of novel topical dermatological therapies, in connection with the sale of $21.3 million of Series B Preferred Stock.
  • Represented Ralexar Therapeutics in connection with a $21.5 million Series A financing.
  • Represented a major French media company in connection with a $20 million Series A financing for a U.S. publisher of music, sports and entertainment web applications.
  • Represented Aclaris Therapeutics in a $21 million Series A financing.
  • Represented a pain pharmaceutical company in a $3 million Series A financing.
  • Represented Ceptaris Therapeutics in a $10 million Series D-1 financing.
  • Represented Ceptaris Therapeutics in a $14.4 million Series D financing.
  • Represented Ception Therapeutics in a $77 million Series C financing.
  • Represented a start-up pharmaceutical company in connection with angel-investor funding.
  • Represented Vicept Therapeutics in two rounds of Series A financing, which raised a total of $16 million.

    • Financings

  • Represented Ceptaris Therapeutics, Inc. in connection with $15 million venture debt financing.
  • Represented Ception Therapeutics in a $12 million venture debt financing.
  • Represented Vicept Therapeutics in a $2.5 million venture debt financing.
  • Represented a manufacturer of avionics in $10 million and $3 million bank loan facilities.
  • Represented a Fortune 100 company in connection with $245 million project financing involving aircraft and a data-processing facility.
  • Represented a real estate development company in connection with a $25 million secured bank loan facility.
  • Represented a Fortune 100 logistics and transportation company in connection with various over-the-counter (OTC) swaps, including interest-rate derivatives, foreign-currency derivatives and equity derivatives conducted pursuant to the International Swaps and Derivatives Association (ISDA).
  • Represented a Fortune 100 company in connection with a $1.5 billion revolving loan facility.
  • Represented a Fortune 100 company in connection with a $1 billion revolving loan facility.

    • Cross-Border Financings

  • Represented a major Canadian bank in connection with a secured lending facility to a Québec company for purposes of an acquisition in the US.
  • Represented a listed French company and its U.S. holding company in connection with a $17 million secured loan from a major U.S. bank.
  • Represented a pharmaceutical company in connection with a $140 million secured debt financing, and the restructuring thereof.
  • Represented a major French CAC 40 company as lender and guarantor in connection with a $230 million project syndicated loan to a wind energy project.
  • Represented Iroko Pharmaceuticals in connection with a cross-border $90 million secured debt financing.
  • Represented a major French company (CAC 40) in connection with guarantees related to two wind energy projects developed by a US subsidiary ($175 million and $63 million).
  • Represented a major Canadian company in connection with secured loans extended by Canadian banks and guaranteed by US subsidiaries of Canadian company (US$400 million; US$200 million; US$75 million).
  • Represented a listed French company in connection with a secured $110 million cross-border facility extended by French banks and guaranteed by US subsidiaries.
  • Represented a subsidiary of a major French company (CAC 40) in connection with a $107 million extension of a letter of credit supporting a waste-to-energy project.
  • Represented a major French company (CAC 40) and its US subsidiary in connection with a $130 million project financing for a waste-to-energy plant.
  • Represented a major US public pension fund in connection with $4.7 billion restructuring of debt of Irish company.
  • Represented a major US pension plan in connection with $120 million convertible notes issued by an Irish company.
  • Represented a Canadian company in connection with $5 million industrial revenue bond financing for a US subsidiary.
  • Represented a Canadian bank in connection with $12 million secured loans guaranteed by US subsidiaries of a Canadian company.
  • Represented a Canadian bank in connection with CAD $5 million loan guaranteed by the US subsidiary of a Canadian company.

    • Corporate Reorganizations

  • Represented major French companies (including one CAC 40 company) in connection with the implementation of tracking stock structures for their respective U.S. holding company.
  • Represented a major French company (CAC 40) in connection with a complete reorganization of the worldwide holdings of a major US subsidiary in order to enable a $1 billion divestiture and a $650 million divestiture.
  • Represented a major French company (CAC 40) in connection with the recapitalization of its US holding company (over $1 billion).
  • Represented a major French company (CAC 40) in connection with the spin-off of a major US subsidiary to a joint venture ($165 million).
  • Represented a major French company (CAC 40) in connection with the reorganization of its US activities.
  • Represented two major French companies (CAC 40) in connection with the spin-off of certain jointly acquired US assets to their respective US subsidiaries.
  • Represented several Canadian companies in connection with "double dip"-driven reorganizations of their US activities.

Admissions

  • Paris, France
  • New York

Education

  • University of Michigan Law School, LL.M., 1981
  • University of Paris-V, LL.B., 1980

Experience

  • Duane Morris LLP
    - Partner, 2001-present; former member of Partners' Board

  • Schnader Harrison Segal & Lewis LLP, Philadelphia, Pennsylvania
    - Partner, 1990-2001
    - Associate, 1986-1989
  • Squire, Sanders & Dempsey, Cleveland, Ohio
    - Associate, 1983-1985

Professional Activities

  • American Bar Association
    - Former Chair, International Law Committee, Young Lawyers Division
  • Philadelphia Bar Association
    - Former Chair, International Law Committee, 1988-1989
  • Legal and Economic Advisor, Cabinet of the Governor of French Guiana, 1981-1983

Civic and Charitable Activities

  • Director, Philadelphia Chapter of French-American Chamber of Commerce
  • Trustee, International House of Philadelphia (2005-2007)
  • Director, French Heritage Society (2006-2009)
  • President, French Benevolent Society of Philadelphia
  • Founder, Director and Vice Chair, Ecole Française Internationale de Philadelphie (1990-2001)

Selected Publications

Selected Speaking Engagements

  • Co-president and speaker, "La Vérification Diligente Corporative," Institut Canadien, Montréal, October 2007
  • Speaker, EFE seminar on "Fusions-Acquisitions," Paris, November 2006
  • Speaker, Legal Aspects of M&A in the U.S., Montréal Chamber of Commerce, October 2006
  • Speaker, "Fusion-Acquisitions en 2006," Institut Canadien, Montréal, October 2006
  • Author and speaker, "International Aspects of M & A", Bisel CLE Institute, Philadelphia 2002
  • Author and speaker, "Transferee Liability in Asset Transactions," Annual PBI Business Lawyers' Institute, Philadelphia, 1998
  • Author and speaker, "Sales of Private and Public Companies by Auction," AIJA Annual Meeting, Amsterdam, 1996
  • Author and speaker, Fundamentals of Structured Finance", The Euromoney Institute of Financial Law, New York, 1995
  • Author and speaker, "Warranties and Disclosures in Corporate Acquisitions," AIJA Annual Meeting, Vichy, 1994